| Cat.No. | Name | Information |
|---|---|---|
| M1959 | Oseltamivir | Oseltamivir is a potent and selective inhibitor of influenza virus neuraminidase enzyme. |
| M5055 | Peramivir | Peramivir is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. |
| M1707 | Entecavir Monohydrate | Entecavir Hydrate is a class of antiviral compounds. |
| M3357 | Telbivudine | Telbivudine (Epavudine) is an orally active, potent antiviral inhibitor of hepatitis B virus (HBV) replication. Telbivudine is an antiviral compound used in hepatitis B research. |
| M1695 | Cidofovir | Cidofovir (Vistide) is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis. |
| M4718 | Dendrobine | Dendrobine is an alkaloid isolated from Dendrobium nobile. Dendrobine has antiviral activity against influenza A virus, IC50 values for A/FM-1/1/47 (H1N1), A/Puerto Rico/8/34 H274Y (H1N1) and A/Aichi/2/68 (H3N2) were 3.39 μM, 2.16 μM and 5.32 μM, respectively. |
| M3222 | Peramivir Trihydrate | Peramivir Trihydrate is a trihydrate of the anti-infection agent peramivir (RWJ-270201,BCX-1812) which is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. |
| M4789 | Isoscopoletin | Isoscopoletin (6-Hydroxy-7-methoxycoumarin) is an active ingredient in artemisia argyi leaves. Isoscopoletin showed significant inhibition of cell proliferation, with IC50 values of 4.0 μM and 1.6 μM against human CCRF-CEM leukemia cells and CEM/ADR5000 drug-resistant subline, respectively. Isoscopoletin (6-Hydroxy-7-methoxycoumarin) has the activity of inhibiting HBV replication. |
| M10082 | Amodiaquine | Amodiaquine is a 4-aminoquinoline compound related to chloroquine, used as an antimalarial and anti-inflammatory agent. |
| M7775 | 3-Deazaadenosine | 3-Deazaadenosine is an inhibitor of S-adenosylhomocysteine hydrolase, with a Ki of 3.9 µM, possesses antiviral activity inhibitor of leukocyte adhesion to TNF-treated endothelial cells. |
| M25132 | Casirivimab | Casirivimab (REGN10933) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Casirivimab lacks efficacy against COVID-19 variants. Casirivimab can be used in combination with Imdevimab , it reduces viral load and improves diseases. |
| M25131 | Imdevimab | Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab , it reduces viral load and improves diseases. |
| M25076 | Enibarcimab | Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research. |
| M25032 | Docaravimab | Docaravimab is an antibody, targeting ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III. Docaravimab can be used in research of Rabies. |
| M25030 | Daxdilimab | Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research. |
| M25021 | Omodenbamab | Omodenbamab is an anti-SpA (Staphylococcal protein A) humanized monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection. |
| M24938 | Maftivimab | Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and Drug Administration (FDA)-approved agent. Maftivimab, also named as Atoltivimab, Odesivimab (Inmazeb), can be used for research of Zaire ebolavirus infection. |
| M24937 | Odesivimab | Odesivimab is a humanized monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection. |
| M24936 | Atoltivimab | Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection. |
| M24890 | Lenvervimab | Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection. |
| M24817 | Lesofavumab | Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody. |
| M24816 | Gedivumab | Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies. |
| M24809 | Gremubamab | Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections. |
| M24804 | Cosfroviximab | Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP). |
| M24803 | Larcaviximab | Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody. |
| M24802 | Porgaviximab | Porgaviximab is a monoclonal antibody that can be used Ebola infection research. |
| M24753 | Suvratoxumab | Suvratoxumab (MEDI4893) is a long-acting, high-affinity humanized anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin or Linezolid . |
| M24748 | Rivabazumab | Rivabazumab is a recombinant antibody against Pseudomonas aeruginosa pcrV. |
| M24737 | Rivabazumab pegol | Rivabazumab pegol is a PcrV protein antibody that can be used to study the phase II pegylated Fab of chronic Pseudomonas aeruginosa infection. |
| M24711 | Regavirumab | Regavirumab (MCA C23) is a human monoclonal antibody against cytomegalovirus (CMV), human serum albumin (HSA) and amino acetic acid. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
